The precise origin of nasopharyngeal cancer remains unclear, but researchers have identified several contributing factors. One of the primary nasopharyngeal cancer causes is infection with the Epstein ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Individuals ...

Statin use during concurrent chemoradiotherapy (CCRT) for advanced nasopharyngeal cancer (NPC) is associated with a 52% reduction in all-cause mortality. Higher cumulative defined daily doses of ...

Researchers have discovered a significant association between specific Epstein-Barr virus (EBV) variants and nasopharyngeal carcinoma (NPC). NPC is a cancer notably prevalent in southern China, where ...

Adjuvant therapy with camrelizumab significantly improved 3-year event-free survival in patients with locoregionally advanced nasopharyngeal carcinoma compared with observation, according to findings ...

Researchers from the University of Hong Kong have discovered that the Epstein-Barr virus (EBV), a common human virus closely linked to nasopharyngeal carcinoma (NPC), can change the 3D structure of ...

The FDA approved the PD-1 inhibitor penpulimab, with two indications, for treating non-keratinizing nasopharyngeal carcinoma (NPC) in adults. No trade name was indicated for the drug. The first ...